Gil Schwartzberg

This profile gathers the share dealings of Gil Schwartzberg in Lixte Biotechnology Holdings, Inc. Between 11 January 2017 and 30 November 2020, the trades on record add up to 5 filings.

No open-market sale appears; the market trades are 3 purchases worth €931k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2020: 1 purchase and no sales on the market.

A typical purchase (the median) is worth €418k. On 2 out of 3 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 7 December 2020, the filings show an open-market purchase worth €418k in Lixte Biotechnology Holdings, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.